Zartash Gul, MD
Hematology & Oncology · Milwaukee, WINPI 1053578625
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $16,636 of the $19,216 with a category attached, or 86.6%. 6 manufacturers reported payments, led by Incyte Corporation at 47.2% of the total. Reporting peaked in 2023 at $6,813 and has fallen 90.5% since, to $650 in 2025.
Across 24 payments — averaging $800.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$9K
- Servier Pharmaceuticals LLC$7K
- E.r. Squibb & Sons, L.L.C.$2K
- Bristol Myers Squibb$842
- Daiichi Sankyo Inc.$650
- Gilead$20
Across 5 payments — averaging $6124.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$22K
- Amgen$5K
- Incyte Corporation$3K
What the payments were for
- Consulting fees$16,63687%
- Travel & lodging$2,07711%
- Food & beverage$4833%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 13 | $9,068 |
| Servier Pharmaceuticals LLC | 3 | $6,660 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,976 |
| Bristol Myers Squibb | 5 | $842 |
| Daiichi Sankyo Inc. | 1 | $650 |
| Gilead | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TIBSOVO$6,660
- JAKAFI$4,498
- Fedratinib$842
- VANFLYTa$650
How this compares
$19,216 in reported general payments places this provider in the 85th percentile of 248 hematology & oncology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ValacyclovirValacyclovir Hcl | 23 | $1,522 |
| Acyclovir | 17 | $431 |
| Hydroxyurea | 18 | $253 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Milwaukee
- Parameswaran HariMilwaukee$1.3M
- Sayed Mehdi HamadaniMilwaukee$546K
- Binod DhakalMilwaukee$535K
- Deepak KilariMilwaukee$359K
- Ehab AtallahMilwaukee$344K
- Nirav ShahMilwaukee$207K
- Razelle KurzrockMilwaukee$199K
- Syed AbutalibMilwaukee$154K
- Patrick FoyMilwaukee$132K
- Guru Subramanian Guru MurthyMilwaukee$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.